{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T16:44:19Z","timestamp":1793724259710,"version":"4.6.1"},"reference-count":44,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T00:00:00Z","timestamp":1782432000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004330","name":"GSK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.ijgc.2026.104774","type":"journal-article","created":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T06:36:48Z","timestamp":1780727808000},"page":"104774","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Poly(adenosine diphosphate-ribose) polymerase inhibitor maintenance therapy with niraparib in patients with primary advanced or recurrent endometrial cancer receiving dostarlimab plus chemotherapy"],"prefix":"10.1016","volume":"36","author":[{"given":"Matthew A.","family":"Powell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharad","family":"Ghamande","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6697-018X","authenticated-orcid":false,"given":"Lars C.","family":"Hanker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Destin","family":"Black","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-2815-655X","authenticated-orcid":false,"given":"Nicoline","family":"Raaschou-Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8605-5472","authenticated-orcid":false,"given":"Lucy","family":"Gilbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6387-9356","authenticated-orcid":false,"given":"David","family":"Cibula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0946-7662","authenticated-orcid":false,"given":"Angeles Alvarez","family":"Secord","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Oaknin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3121-4605","authenticated-orcid":false,"given":"Robert W.","family":"Holloway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-1462-0750","authenticated-orcid":false,"given":"Hanne F.","family":"Mathiesen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-4011-270X","authenticated-orcid":false,"given":"Joseph","family":"Buscema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Kristeleit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudarshan","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4857-6346","authenticated-orcid":false,"given":"Ingrid A.","family":"Boere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7241-3096","authenticated-orcid":false,"given":"Brian","family":"Slomovitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Gennigens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert L.","family":"Coleman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Heitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joyce N.","family":"Barlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siarhei","family":"Mavrichev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Berek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Jos\u00e9","family":"Bermejo-P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanne","family":"Weberpals","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Savarese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Maret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaitlin","family":"Yablonski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosemary","family":"Schroyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Austin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio","family":"Valabrega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trine","family":"N\u00f8ttrup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ijgc.2026.104774_bib1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"10.1016\/j.ijgc.2026.104774_bib2","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.3390\/cancers17061035","article-title":"Trends in endometrial cancer incidence among premenopausal and postmenopausal women in the United States between 2001 and 2021","volume":"17","author":"Guo","year":"2025","journal-title":"Cancers"},{"issue":"8","key":"10.1016\/j.ijgc.2026.104774_bib3","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s00432-025-06277-9","article-title":"Global, regional, and national burden of ovarian cancer in women aged 45+from 1990 to 2021 and projections for 2050: a systematic analysis based on the 2021 global burden of disease study","volume":"151","author":"Ren","year":"2025","journal-title":"J Cancer Res Clin Oncol"},{"issue":"11","key":"10.1016\/j.ijgc.2026.104774_bib4","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1200\/JCO.2004.07.184","article-title":"Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group study","volume":"22","author":"Fleming","year":"2004","journal-title":"J Clin Oncol"},{"issue":"33","key":"10.1016\/j.ijgc.2026.104774_bib5","doi-asserted-by":"crossref","first-page":"3841","DOI":"10.1200\/JCO.20.01076","article-title":"Carboplatin and paclitaxel for advanced endometrial cancer: final overall survival and adverse event analysis of a phase III trial (NRG Oncology\/GOG0209)","volume":"38","author":"Miller","year":"2020","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.ijgc.2026.104774_bib6","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.annonc.2022.05.009","article-title":"Endometrial cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Oaknin","year":"2022","journal-title":"Ann Oncol"},{"issue":"23","key":"10.1016\/j.ijgc.2026.104774_bib7","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1056\/NEJMoa2216334","article-title":"Dostarlimab for primary advanced or recurrent endometrial cancer","volume":"388","author":"Mirza","year":"2023","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.ijgc.2026.104774_bib8","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.annonc.2024.05.546","article-title":"Overall survival in patients with endometrial cancer treated with dostarlimab plus carboplatin-paclitaxel in the randomized ENGOT-EN6\/GOG-3031\/RUBY trial","volume":"35","author":"Powell","year":"2024","journal-title":"Ann Oncol"},{"issue":"23","key":"10.1016\/j.ijgc.2026.104774_bib9","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1056\/NEJMoa2302312","article-title":"Pembrolizumab plus chemotherapy in advanced endometrial cancer","volume":"388","author":"Eskander","year":"2023","journal-title":"N Engl J Med."},{"issue":"3","key":"10.1016\/j.ijgc.2026.104774_bib10","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1200\/JCO.23.02132","article-title":"Durvalumab plus carboplatin\/paclitaxel followed by maintenance durvalumab with or without olaparib as first-line treatment for advanced endometrial cancer: the phase III DUO-E trial","volume":"42","author":"Westin","year":"2024","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.ijgc.2026.104774_bib11","doi-asserted-by":"crossref","first-page":"e423","DOI":"10.1016\/S1470-2045(25)00167-6","article-title":"ESGO-ESTRO-ESP guidelines for the management of patients with endometrial carcinoma: update 2025","volume":"26","author":"Concin","year":"2025","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.ijgc.2026.104774_bib12","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.32604\/or.2025.061120","article-title":"Drug discovery in advanced and recurrent endometrial cancer: recent advances","volume":"33","author":"Francoeur","year":"2025","journal-title":"Oncol Res"},{"issue":"6","key":"10.1016\/j.ijgc.2026.104774_bib13","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-006624","article-title":"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gynecologic cancer","volume":"11","author":"Disis","year":"2023","journal-title":"J Immunother Cancer"},{"issue":"8","key":"10.1016\/j.ijgc.2026.104774_bib14","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.3390\/biom12081031","article-title":"Dostarlimab: a review","volume":"12","author":"Costa","year":"2022","journal-title":"Biomolecules"},{"key":"10.1016\/j.ijgc.2026.104774_bib15","unstructured":"Jemperli product information. GSK. Accessed February 2, 2026. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/761174s009lbl.pdf."},{"key":"10.1016\/j.ijgc.2026.104774_bib16","unstructured":"Jemperli summary of product characteristics. GSK. Accessed February 2, 2026. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/jemperli-epar-product-information_en.pdf."},{"key":"10.1016\/j.ijgc.2026.104774_bib17","doi-asserted-by":"crossref","DOI":"10.1177\/17588359241255174","article-title":"PARP inhibitors in non-ovarian gynecologic cancers","volume":"16","author":"Fernandes","year":"2024","journal-title":"Ther Adv Med Oncol"},{"issue":"4","key":"10.1016\/j.ijgc.2026.104774_bib18","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s11523-023-00970-w","article-title":"PARP inhibitors in ovarian cancer: a review","volume":"18","author":"O\u2019Malley","year":"2023","journal-title":"Target Oncol"},{"issue":"suppl 16","key":"10.1016\/j.ijgc.2026.104774_bib19","article-title":"Prevalence of homologous recombination deficiency in different molecular subgroups of endometrial carcinomas","volume":"43","author":"Rao","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijgc.2026.104774_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103516","article-title":"16P Homologous recombination deficiency in endometrial cancer: association with clinical and molecular characteristics","volume":"9","author":"Shen","year":"2024","journal-title":"ESMO Open"},{"key":"10.1016\/j.ijgc.2026.104774_bib21","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1335196","article-title":"How BRCA and homologous recombination deficiency change therapeutic strategies in ovarian cancer: a review of literature","volume":"14","author":"Arcieri","year":"2024","journal-title":"Front Oncol"},{"issue":"11","key":"10.1016\/j.ijgc.2026.104774_bib22","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1158\/2159-8290.CD-15-0714","article-title":"Homologous recombination deficiency: exploiting the fundamental vulnerability of ovarian cancer","volume":"5","author":"Konstantinopoulos","year":"2015","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ijgc.2026.104774_bib23","doi-asserted-by":"crossref","first-page":"6123","DOI":"10.2147\/CMAR.S221001","article-title":"PARP inhibitors in endometrial cancer: current status and perspectives","volume":"12","author":"Musacchio","year":"2020","journal-title":"Cancer Manag Res"},{"key":"10.1016\/j.ijgc.2026.104774_bib24","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.816642","article-title":"Targeting PARP1 to enhance anticancer checkpoint immunotherapy response: rationale and clinical implications","volume":"13","author":"Wanderley","year":"2022","journal-title":"Front Immunol"},{"issue":"24","key":"10.1016\/j.ijgc.2026.104774_bib25","doi-asserted-by":"crossref","first-page":"6717","DOI":"10.1158\/0008-5472.CAN-18-2652","article-title":"Development of PARP and immune-checkpoint inhibitor combinations","volume":"78","author":"Stewart","year":"2018","journal-title":"Cancer Res"},{"issue":"24","key":"10.1016\/j.ijgc.2026.104774_bib26","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1101\/gad.252478.114","article-title":"PTIP associates with Artemis to dictate DNA repair pathway choice","volume":"28","author":"Wang","year":"2014","journal-title":"Genes Dev"},{"key":"10.1016\/j.ijgc.2026.104774_bib27","article-title":"PARP inhibitor resistance in breast and gynecological cancer: resistance mechanisms and combination therapy strategies","volume":"13","author":"Wang","year":"2022","journal-title":"Front Pharmacol"},{"issue":"2","key":"10.1016\/j.ijgc.2026.104774_bib28","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.ygyno.2022.02.025","article-title":"Efficacy and safety of durvalumab with olaparib in metastatic or recurrent endometrial cancer (phase II DOMEC trial)","volume":"165","author":"Post","year":"2022","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104774_bib29","doi-asserted-by":"crossref","first-page":"7950","DOI":"10.1038\/s41467-025-62678-x","article-title":"Maintenance olaparib after platinum-based chemotherapy for advanced\/metastatic endometrial cancer: GINECO randomized phase IIb UTOLA trial","volume":"16","author":"Joly","year":"2025","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104774_bib30","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1038\/s41467-025-56914-7","article-title":"Olaparib combined to metronomic cyclophosphamide and metformin in women with recurrent advanced\/metastatic endometrial cancer: the ENDOLA phase I\/II trial","volume":"16","author":"Piffoux","year":"2025","journal-title":"Nat Commun"},{"key":"10.1016\/j.ijgc.2026.104774_bib31","unstructured":"GSK. A study to evaluate dostarlimab plus carboplatin-paclitaxel versus placebo plus carboplatin-paclitaxel in participants with recurrent or primary advanced endometrial cancer (RUBY). ClinicalTrials.gov. Accessed December 14, 2025. https:\/\/clinicaltrials.gov\/study\/NCT03981796."},{"key":"10.1016\/j.ijgc.2026.104774_bib32","unstructured":"Imfinzi. Summary of product characteristics. Astra Zeneca. Accessed February 2, 2026. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/imfinzi-epar-product-information_en.pdf."},{"key":"10.1016\/j.ijgc.2026.104774_bib33","unstructured":"Imfinzi: prescribing information. Astra Zeneca. Accessed February 2, 2026. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/761069s050lbl.pdf."},{"key":"10.1016\/j.ijgc.2026.104774_bib34","article-title":"Efficacy and safety of PARP inhibitors in advanced or recurrent endometrial cancer: a systematic review and meta-analysis","volume":"16","author":"Zhang","year":"2025","journal-title":"Front Immunol"},{"key":"10.1016\/j.ijgc.2026.104774_bib35","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.ygyno.2025.07.008","article-title":"A phase II, randomized, double-blind study of the use of Rucaparib vs. placebo maintenance therapy in metastatic and recurrent endometrial cancer","volume":"200","author":"Corr","year":"2025","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1016\/j.ijgc.2026.104774_bib36","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.ygyno.2020.12.010","article-title":"Clinical significance of homologous recombination deficiency score testing in endometrial cancer","volume":"160","author":"Siedel","year":"2021","journal-title":"Gynecol Oncol"},{"issue":"2","key":"10.1016\/j.ijgc.2026.104774_bib37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.17.00286","article-title":"Prevalence of homologous recombination-related gene mutations across multiple cancer types","volume":"2018","author":"Heeke","year":"2018","journal-title":"JCO Precis Oncol"},{"issue":"3","key":"10.1016\/j.ijgc.2026.104774_bib38","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1002\/pros.24454","article-title":"Differential responses to taxanes and PARP inhibitors in ATM- versus BRCA2-mutated metastatic castrate-resistant prostate cancer","volume":"83","author":"Su","year":"2023","journal-title":"Prostate"},{"issue":"6","key":"10.1016\/j.ijgc.2026.104774_bib39","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1007\/s11523-025-01183-z","article-title":"Targeting DNA damage repair pathways beyond PARP inhibition","volume":"20","author":"Merry","year":"2025","journal-title":"Target Oncol"},{"issue":"5","key":"10.1016\/j.ijgc.2026.104774_bib40","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1038\/s41591-025-03566-1","article-title":"Pembrolizumab plus chemotherapy in advanced or recurrent endometrial cancer: overall survival and exploratory analyses of the NRG GY018 phase 3 randomized trial","volume":"31","author":"Eskander","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.ijgc.2026.104774_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103540","volume":"9","author":"Van Nieuwenhuysen","year":"2024","journal-title":"ESMO Open"},{"issue":"19","key":"10.1016\/j.ijgc.2026.104774_bib42","doi-asserted-by":"crossref","DOI":"10.3390\/ijms231911684","article-title":"TCGA molecular prognostic groups of endometrial carcinoma: current knowledge and future perspectives","volume":"23","author":"Arciuolo","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"5","key":"10.1016\/j.ijgc.2026.104774_bib43","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1093\/annonc\/mdy058","article-title":"Final validation of the ProMisE molecular classifier for endometrial carcinoma in a large population-based case series","volume":"29","author":"Kommoss","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ijgc.2026.104774_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2025.115329","article-title":"Immunotherapy and PARP inhibitors as first-line treatment in endometrial cancer: a systematic review and network meta-analysis","volume":"220","author":"Villacampa","year":"2025","journal-title":"Eur J Cancer"}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X26003051?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X26003051?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T21:43:01Z","timestamp":1785966181000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X26003051"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":44,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S1048891X26003051"],"URL":"https:\/\/doi.org\/10.1016\/j.ijgc.2026.104774","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Poly(adenosine diphosphate-ribose) polymerase inhibitor maintenance therapy with niraparib in patients with primary advanced or recurrent endometrial cancer receiving dostarlimab plus chemotherapy","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijgc.2026.104774","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of European Society of Gynaecological Oncology and the International Gynecologic Cancer Society.","name":"copyright","label":"Copyright"}],"article-number":"104774"}}